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Introduction 
The incidence and severity of haemolytic disease of the newborn (HDN) has reduced 
significantly since the introduction of prophylactic anti-D in the late 1960s (Mackenzie et al. 
1999). UK guidelines recommend that pregnant women should have ABO/D grouping and 
antibody screening at 10-16 weeks and at 28 weeks of pregnancy (White et al. 2016; NICE 
guidelines 2015). For those who have anti-D, anti-c and anti-K laboratory monitoring should 
be continued monthly up to 28 weeks, and fortnightly thereafter (White et al. 2016;). If 
maternal alloantibody levels rise significantly during pregnancy referral to a foetal medicine 
unit is recommended. The foetus is monitored for signs of anaemia using Doppler 
ultrasonography, which measures the peak systolic velocity of the middle cerebral artery 
(MCA-PSV). At birth, infants born to women who have clinically significant antibodies are 
examined for signs of HDN and DAT from the cord sample is performed: if this is positive 
haemoglobin and bilirubin levels are measured.  
The aims of this retrospective study were to estimate the incidence of maternal, clinically 
significant alloantibodies in a large tertiary referral centre, characterise their specificity, 
describe the clinical outcome of the foetus/neonates and identify areas for change. 
 
Method 
The study met criteria for service evaluation under the Research Ethics Service 
guidance, so no research and ethical review approval was required. Data from 
transfusion laboratory information system (Winpath Version 5) was used to identify pregnant 
women who had clinically significant antibodies between 2003 and 2013, while 
foetal/neonatal outcome were collected from patients’ electronic records and clinical notes 
for the years 2008-2013.. The ABO/RhD blood grouping and antibody screening of women 
were checked at booking and 28 weeks as recommended by national guidelines (White et al 
2016). ABO grouping and antibody identification were determined using Immucor NEO 
analyzer, a closed system that utilizes CAPTURE® technology (solid phase) to identify 
clinically significant antibodies (IBG Immuncor Ltd.4, Riverside Business Centre, Brighton, 
BN43 6RE).    
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Data for Doppler MCA-PSV results were collected from the foetal maternal unit using 
antenatal clinic record system. This included all MCA-PSV ultrasound results (Vmax) and 
ultrasound opinions on whether the scan showed evidence of foetal anaemia or hydrops.  
 
Definitions:  
Antibodies were divided into the following groups ( Chandrasekar et al. 2001):  
Group-1: anti-D, anti-c and anti-K 
Group-2: anti-Fya, anti-Fyb, anti-Jka, anti-Jkb, anti-C, anti-Ce, anti-e, anti-E, anti-Cw 
Group-3: anti-M, anti-N, anti-Kpa, anti-S, anti-Lea and anti-Leb  (non-significant as don’t 
cross placenta) 
 
Neonatal anaemia was defined as:  
- at birth, capillary Haemoglobin (Hb) of < or = to14.0 x 109g/dl 
- at less than a week old, Hb < or = to 15.0 x 109g/dl 
- at 2 weeks and under, Hb < or = to 13.5 x 109g/dl   
 
Results 
From 2003 to 2013 we identified 154 women with clinically significant maternal 
alloantibodies (out of 21,665 women), giving a prevalence of 0.71% (95% CI 0.60 - 0.82). 
The most common were anti-E (23%), anti-D (12%), anti-K (9%) and anti-c (8%). 
Foetal/ Neonatal outcomes 
We excluded fifteen women due to terminations, miscarriages, ectopic pregnancies and still 
births (unrelated to HDN), leaving 139 cases. 92 (66%) had previous pregnancies and 8 (6%) 
acquired the alloantibodies from blood transfusion (4 anti-E, 2 anti-K, 1 anti-D + anti-K, and 
1 anti-c). Paternal testing was performedin 54/73 (74%) cases this was found to be the cause 
of maternal alloantibodies. 
 
There were no foetal or neonatal deaths attributed to maternal red cell alloimmunisation. Due 
to significant increase in alloantibody levels 49 (35%) women underwent Doppler ultrasound 
MCA-PSV, and six (12%) were diagnosed as having foetal anaemia.  There was one 
intrauterine transfusion at 32 weeks, the rest delivered urgently (two at 34 weeks, two at 36 
weeks, one unknown).  One neonate was subsequently treated for sepsis post-delivery. 
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In total there were 124 babies delivered (15 missing), of these 25 (20%) were anaemic. Direct 
antiglobulin test (DAT) was positive in 49/109 (45%) at delivery with the most frequent 
alloantibodies being anti-D (n=16), anti-E (n=16), other group-2 antibodies (n = 15, DC, Jkb 
CD, Jka, E Jkb) anti-c (n=9).  
 
Of the neonates that were found to be anaemic, DAT was positive in 21/25 (84%), and the 
eluate confirmed maternal alloantibodies as the cause for anaemia in these babies. Three 
(12%) had exchange transfusions and nine (36%) required top up transfusions. Before 
discharge 15 more babies became anaemic (12%). The development of anaemia ranged from 
day one to 32; two of these babies required top-up transfusion. 
 
Discussion  
The prevalence of maternal clinical significant antibodies in our institution was 0.7%, with 
the Rh system being the most common antibodies. These results are consistent with other 
studies (Smith et al. 2015; Pal et al. 2013; Foudoulaki-Paparizos et al. 2013). Of six cases 
that were diagnosed with foetal anaemia by US Doppler, five were due to Rh antibodies and 
one to anti-K. Current UK guidelines recommend that regular monitoring is performed only 
for anti-D, anti-K and anti-c antibodies (White et al. 2016). Our results, and those of others, 
suggest that regular laboratory monitoring could be justified for all Rhesus antibodies, and in 
particular for anti-E antibody (Smith et al. 2015; Fan et al. 2014; Pal et al. 2013). 
 
While the overall incidence of anti-D has reduced significantly with the introduction of 
immune prophylaxis, it is still the single most common cause of neonatal morbidity. In this 
study anti-D accounted for 40% of neonatal anaemia, 55% of top up transfusions, 33% of 
exchange transfusions and the only case that required intrauterine transfusion. 
In the UK it is recommended that all women of childbearing age are transfused Rh D and K 
compatible red cells. In this study only two out of eight cases that we identified to have 
acquired antibodies from previous transfusion cases were due to anti-K, and anti-K plus anti-
D, suggesting that this has had a positive impact on outcome.  A potential explanation for 
these two cases may be transfusion abroad.  
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Another important finding was the development of neonatal anaemia after birth in 12% of 
cases. As current guidelines only recommend a blood test at delivery a significant minority of 
neonatal anaemia may be missed. It was not possible to comment specifically on the time 
course of when this developed from our data as monitoring of neonatal haemoglobin was 
variable and intermittent. Further haemoglobin monitoring during the neonatal period in 
babies with maternal alloantibodies could be introduced to avoid missing this group. 
 
We identified two outcomes to recommend a change in practice. Firstly, that adverse neonatal 
outcomes were associated with all Rhesus groups and we suggest that regular laboratory 
monitoring in pregnancy should be carried out on all these groups, particularly anti-E. 
Secondly, a significant proportion of neonates developed anaemia after delivery and may be 
missed if following current guidelines. Further work is needed to evaluate the time course of 
this and to identify an appropriate monitoring schedule. 
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Neonatal Outcome (n = denominator) Cases Comments 
Ultrasound Doppler MCA PSV raised 
(n=49) 
6 (12.2%) 2 anti-D, 1 anti-c, 1 anti-E and anti-c, 1 anti-K, and 1 anti-D, anti-Jkb and 
anti-c. 
Intra uterine transfusion 1 (2%) Anti-D 
Anaemic (n=82) 
25 (30%) 
9 anti-D, 4 anti-D + other, 3 anti-E, 1 
anti E + other, 6 group -2 Ab, 4 anti-
c, 2 anti-E, 1 anti-K and 1 group-3 
Ab 
Raised bilirubin (n=82) 28 (60%)  
DAT Positive (n=109) 
49 (45%) 
42/49 had maternal Ab detected by 
eluate 
Top up Transfusion (n=124) 9 (6.5%) 4 anti-D, 3 anti-D +other, 2 anti-E 
Exchange Transfusion (n  124) 3 (2%) 1 anti-D, 1 anti-E, 1 anti-D/anti-C 
Footnote: The denominator varies for several reasons, including some for which data were ‘not 
available’ 
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Table 1:  Foetal and Neonatal outcome data  
 
 
 
 
 
 
